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E-mail address: janaina.anjos@ufpe.br (J.V. dos AnPyrimidines and their oxo-derivatives are well researched due to their anti-inﬂammatory, analgesic, anti-
microbial, antiviral, and interferon inducing activities. New pyrimidine derivatives are therefore fre-
quently synthesized to build up small molecule libraries for the discovery of drug candidates.
Synthesis of 2,6-diaryl-4-(3H)-pyrimidinones and 2,6-diaryl-4-aminopyrimidines is traditionally a
2-day laboratory effort carried out in two steps, always using ethanol as solvent, and triethylamine as
base. In this Letter, we advance a one-step alternative synthetic method with a 40 min reaction time
using a microwave reactor in an aqueous media with potassium carbonate as base. The average yields
were also somewhat improved. This new method thus emerges as more eco-friendly, not only because
it does not employ triethylamine as base, but also due to a much reduced usage of organic solvents, lead-
ing to less harmful residues. Using this method, we synthesized twenty pyrimidine derivatives with
antinociceptive activities in satisfactory chemical yields.
 2013 Elsevier Ltd. All rights reserved.Introduction
Pyrimidines and their oxo derivatives are six-membered het-
erocycles of importance to medicinal chemistry due to their biolog-
ical activities. They are closely related to nucleic acids, since they
are very much alike in structure to the pyrimidine bases.1 Perhaps,
because of this structural similarity, compounds with such hetero-
cycles in their molecular structure were reported as antitumor,2,3
interferon inducer,4 antiviral,5 anti-hipertensive,6 hypoglycemic,7
anticonvulsant,8 antinociceptive,9,10 and anti-inﬂammatory11
agents.
Risperidone (I), bropirimine (II), and 5-ﬂuorouracil (III) are
three successful examples of therapeutical tools that contain the
pyrimidinone nucleus in their structures (Fig. 1). Risperidone is
an atypical second-generation antipsychotic drug used in the treat-
ment of schizophrenia, and bipolar and behavior disorders.12 Other
examples are bropirimine and 5-ﬂuorouracil, which are both anti-
cancer agents.13,14
Pyrimidine or pyrimidinone scaffolds can be prepared in differ-
ent ways.1 Usually, a Michael adduct and an uronium-containing
molecule (guanidine,15 amidines,16 urea,17 thiourea, and their
derivatives18,19) are condensed in the presence of an organic base
to prepare the heterocyclic nucleus. In general, this process may
take about two days of laboratory work for the preparation ofll rights reserved.
x: +55 81 2126 8440.
jos).one sole product.1,2,9–11,16 Faster synthetic routes are thus desir-
able to prepare such bio-active heterocycles.
Microwave radiation has been used since the 1980’s as an alter-
native manner to accelerate endothermic organic reactions.20
Microwave radiation can be focused in the reaction medium and
efﬁciently transfer energy directly to the reacting species, super-
heating them in a much faster manner, when compared to regular
convection heating,20 thereby facilitating the desired chemical
transformations. As a result, many organic reactions have been
performed using microwave energy, like cycloadditions,21 addi-
tions to carbonyl group,22 electrophylic substitutions,23 and het-
erocycle synthesis.24
Multicomponent reactions (MCRs) are one-pot reactions that
begin with three or more reagents that are mixed together, but
react in sequence. In general, these reactions are driven by an
irreversible step that precedes equilibrium in favor of the ﬁnal
product.25 The use of microwave energy could accelerate this type
of reaction since the conductive heating could improve the rate
determining step for the overall process. Having this in mind,
Matloobi and Kappe, for example, used microwave irradiation to
perform the synthesis of several 2-amino-4-arylpyrimidine deriva-
tives through a Biginelli multicomponent approach.26
Our research group has been involved in synthesizing and test-
ing the biological activities of pyrimidines and their oxo deriva-
tives.10,11,16 Some of the products we designed and prepared
presented relevant antinociceptive activities.10 However, the
methodology employed for the synthesis of such products is quite
laborious and requires two or more steps to ﬁnish the whole
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Figure 1. Some examples of drugs containing the pyrimidine scaffold.
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Scheme 1. Three-component reaction of aromatic aldehydes, ethyl cyanoacetate,
and benzamidine.
Table 1
Microwave assisted multicomponent reaction for the
synthesis of 6-oxo-2,4-diaryl-1,6-dihydro-pyrimidine-5-
carbonitriles (7a–j)
Compound Ar Yield (%)
7a Ph 42
7b m-Tolyl 47
7c p-Tolyl 33
7d p-ClPh 49
7e p-BrPh 46
7f p-FPh 45
7g p-OCH3Ph 41
7h m-NO2Ph 20
7i p-NO2Ph 43
7j 3,4-diClPh 51
A. L. Xavier et al. / Tetrahedron Letters 54 (2013) 3462–3465 3463synthetic process.16 Indeed, synthesis of 2,6-diaryl-4-(3H)-pyri-
midinones and 2,6-diaryl-4-aminopyrimidines is traditionally a
two-day effort carried out in two steps always using ethanol as sol-
vent and triethylamine as base: in the ﬁrst, one obtains the alicy-
clic derivative from aromatic aldehydes and a methylene-active
compound, and, in the second, a condensation of this alicyclic
derivative with an uronium donor is performed, followed by an
intramolecular cyclization.
Thus, the development of multicomponent methods for the pro-
duction of these bioactive heterocycles will speed up the synthetic
part of the discovery process for new pyrimidinic drugs.27Ph
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Scheme 2. Mechanism of formatioAccordingly, in this Letter we report our development of a new,
multicomponent, and eco-friendly methodology route for the syn-
thesis of 4-amino-2,6-diaryl-pyrimidine-5-carbonitrile and 6-oxo-
2,4-diaryl-1,6-dihydro-pyrimidine-5-carbonitrile derivatives.
Some of these derivatives have shown signiﬁcant analgesic activity
in mice.10
Results and discussion
In our synthetic approach, aromatic aldehydes (4a–j) were
allowed to react with ethyl cyanoacetate (5) and benzamidine
hydrochloride (6), in the presence of potassium carbonate as base.
The reaction was performed in water, under microwave irradiation
and led to the pyrimidinones 7a–j in moderate yields (Scheme 1,
Table 1).28,29
The reaction conditions using microwave irradiation were opti-
mized with benzaldehyde. Under microwave irradiation, the reac-
tion took place in about 40 min.
In order to be able to compare the methods, we also performed
the same reaction without microwave irradiation, using the same
solvent (water) and the same quantities for the reagents and benz-
aldehyde, in reﬂux. For 6-oxo-2,4-diphenyl-1,6-dihydro-pyrimi-
dine-5-carbonitrile (7a), the yield was only 18%, 8 h after the
beginning of the reaction.
In both cases, there are, possibly, two subsequent reactions
occurring in order to arrive at the heterocycle scaffold: the ﬁrst
one is the Knoevenagel reaction,30 where an aromatic aldehyde
reacts with ethyl cyanoacetate, a so called ‘methylene active’ com-
pound because of its easily deprotonable central methylene group,
to form Michael’s intermediate. Once formed, the Knoevenagel ad-
duct can react with benzamidine. Michael’s adduct can then be at-
tacked by the lone electron pair of a nitrogen atom in the uronium
portion. There is then a sequence of additions with a subsequent
ring closure to form the corresponding heterocycle. However, the
last step in this mechanistic explanation for the pyrimidinone scaf-
fold formation is quite intriguing. According to Mendonça et al.,16NH2
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Scheme 3. Another mechanistic explanation for the formation of 2,6-diaryl-4-(3H)-pyrimidinones.
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Scheme 4. Synthesis of 2,6-diaryl-4-aminopyrimidines via multicomponent
reaction.
3464 A. L. Xavier et al. / Tetrahedron Letters 54 (2013) 3462–3465atmospheric oxygen is responsible for this oxidation and loss of a
H2 molecule, leading to the heterocycle (Scheme 2).
Another mechanismwhich can also explain the formation of the
title compounds is the formation of an imine derivative which
takes place as a ﬁrst step. This intermediate can be produced by
the reaction between the aldehyde and the amidine. Then, a subse-
quent reaction of this imine derivative with ethyl cyanoacetate
forms the desired heterocycle. Once again, in a process analogous
to the pyrimidinone ring formation, oxygen can perform the oxida-
tion of the dihydro derivative to a pyrimidine nucleus in the last
step (Scheme 3).
In order to expand this reaction proﬁle to similar scaffolds, we
tested the protocol changing the ‘‘methylene active’’ compound
and thus, building the pyrimidine nucleus (9a–j). To achieve this
goal, the aromatic aldehydes reacted with malononitrile (8) and
benzamidine under the same reaction conditions (Scheme 4, Table
2).28,29
Some of the pyrimidinone derivatives described herein (7a, 7d,
and 7g) had their antinociceptive activity evaluated in mice
through acetic acid induced stimuli.10 It was reported that, at the
dose of 50 mg/kg, pyrimidinone 7a showed 85% of analgesia, thus
more potent than indomethacin (76% of activity, in comparison
to non-treated animals), the reference drug. It is suggested thatTable 2
Microwave assisted multicomponent reaction for the
synthesis of 4-amino-2,6-diaryl-pyrimidine-5-carbonitr-
iles (9a–j)
Compound Ar Yield (%)
9a Ph 56
9b m-Tolyl 36
9c p-Tolyl 47
9d p-ClPh 70
9e p-BrPh 48
9f p-FPh 27
9g p-OCH3Ph 48
9h m-NO2Ph 40
9i p-NO2Ph 67
9j 3,4-diClPh 22some compounds that contain the pyrimidinone scaffold may
interfere with the acute inﬂammatory response induced by acetic
acid, inhibiting or modulating the migration or production of
chemical mediators in the inﬂammatory site.11,31,32
Conclusions
In short, we advanced in this article a multicomponent
approach employing microwave energy and water as solvent to
synthesize pyrimidines and their oxo-derivatives. This environ-
mentally friendlier protocol furnishes products with higher chem-
ical yields, employs potassium carbonate as base instead of
triethylamine, and is performed in 40 min, showing to be much
faster than the usual 2 day route. We exempliﬁed this synthetic
methodology by preparing 20 different 2,6-diaryl-4-(3H)-pyrimid-
inones and 2,6-diaryl-4-aminopyrimidines with antinociceptive
activities, in satisfactory chemical yields.
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